Sanofi (SNW) Fair Value & Analysis
Healthcare · DE · Market cap €109B
What is Sanofi really worth?
A solid business, trading 19% below our fair value of €94.36.
As of Aug 14, 2026, the fair value of Sanofi is €94.36 per share against a price of €76.21, so the fair value sits 24% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 14, 2026
From 23 valuation models · updated 23 days ago
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A fairly wide model range (€61.69 to €130.02) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range €64.73 – €99.87 · fair‑value band €61.69 – €130.02 · the €76.21 price screens below the €94.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.
Analysis
Sanofi (SNW) currently trades at €76.21, while our model-based Fair Value estimate is €94.36, implying the stock looks roughly 19.2% undervalued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of €99.49 per share, and 16 of the 23 models we run sit above the €76.21 price. Bear case: the Asset-Based group reads lowest at €33.55, and 7 of the 23 models stay below the price. Evidence for this calculation is low.
Net debt stands at €10.9B. Fundamentals as of Aug 14, 2026
Our scenario range runs from €61.69 (bear case) to €130.02 (bull case); at €76.21, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at 24%, SNW screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 23 models by family
Widest divergence: Growth Earnings (€99.49) versus Asset-Based (€33.55). Highest evidence: FCF DCF (80).
Notify me when SNW reaches fair value
Put SNW on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
There is no Profile data available for SNW.HA.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sanofi reported revenue of €46.7B in FY2025 versus €39.2B in FY2021, a compound +4.5%/yr. Reported net income was €7.8B in FY2025, compounding +5.9%/yr from FY2021.
Watch SNW: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Global Aplastic Anemia Industry Trends and Growth Outlook 2025-2035 Featuring Profiles of Pfizer, Novartis, and Sanofi
- Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,176 | $389.47 | −67% |
| Johnson & Johnson, JNJ | $275.23 | $169.04 | −39% |
| AbbVie Inc ABBV | $256.46 | $67.72 | −74% |
| Roche Holding RO | CHF 374.60 | CHF 306.54 | −18% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 123.74 | CHF 114.90 | −7% |
| Novo Nordisk A/S NOVOB | kr 295.50 | kr 409.46 | +39% |
| Amgen Inc AMGN | $437.23 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $151.00 | $146.50 | −3% |
| Pfizer Inc PFE | $28.02 | $24.87 | −11% |
Compare Sanofi with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sanofi (SNW) overvalued or undervalued?
What is the fair value of SNW?
What is the quality score of SNW?
What is the price target for Sanofi (SNW)?
What is the Sanofi stock forecast for 2026?
What is the net profit margin of SNW?
Does Sanofi pay a dividend?
Watch Sanofi in the live analysis
One click puts Sanofi on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.